Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.
SfN Poster | Genes regulating cytoskeleton organization identified as neuro-common drivers of blood NfL change rate and disease-specific clinical progression in AI driven Digital Twins
X. SHEN, D. SHOKEEN, O. ISACSON, R. HARRISON, S.-Y. SHIN, J. LATOURELLE
Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia’s Digital Twins to be Presented at SfN 2023
Somerville, MA, November 8, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer’s Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from […]
MDS Poster | Gemini Digital Twins Identified Neuro-Common and Disease-Specific Drivers of Blood NfL Change Rate
X.Shen, S.Sathe, L.Sun, P.Ashrap, K.Johnson, S.Sukhram, S.Reddy, S-Y.Shin, J.Latourelle, C.Sampaio
AI-Driven Discovery of Novel Predictors of Parkinson’s Disease Progression by GNS Healthcare Appears in The Lancet Neurology
Discovery May Accelerate the Development of New Drugs & Better Match New Drugs to Individual Patients CAMBRIDGE, Mass.– Sept 26, 2017 – GNS Healthcare (GNS), a leading precision medicine company, announced today the discovery of genetic and molecular markers of faster motor progression of Parkinson’s Disease (PD) patients, the LINGO2 gene together with a second genetic […]